Vertex Pharmaceuticals valuation
Valuation
The P/E ratio is 34.4. The average price target of 28 analysts is $595.36.
Data as of November 18, 2026
Vertex Pharmaceuticals compared with similar companies
Vertex Pharmaceuticals's P/E (trailing 12 months): 34.4, in line with the median of a group of 7 similar companies (34.4).
| Metric | Vertex Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 34.4 | 34.4 | 27.0 – 49.1 | Middle |
| Forward P/E | 26.8 | 21.0 | 13.8 – 31.0 | Middle |
| EV/EBITDA | 26.6 | 22.7 | 17.0 – 26.1 | High |
| Price/book | 6.48 | 7.12 | 5.30 – 14.1 | Middle |
| Price/sales | 10.5 | 10.3 | 6.15 – 17.1 | Middle |
| Gross margin | 54.8% | 56.0% | 23.4% – 80.8% | Middle |
| Operating margin | 37.8% | 19.5% | -61.2% – 32.1% | High |
| Net margin | 30.7% | 13.9% | 0.0% – 29.6% | High |
| ROE | 20.8% | 10.0% | -28.0% – 17.5% | High |
| Debt/equity | 0.31 | 0.35 | 0.05 – 0.73 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Vertex Pharmaceuticals: valuation over time
On the latest fiscal year's earnings (2025), Vertex Pharmaceuticals's P/E today is 35.0, above the median of its last 8 fiscal years (26.8; between 20.5 and 144.1 from 2017 to 2025). Relative to earnings, the stock costs more than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $453.36 | $15.32 | 29.6 |
| 2024 | $402.70 | -$2.08 | — |
| 2023 | $406.89 | $13.89 | 29.3 |
| 2022 | $288.78 | $12.82 | 22.5 |
| 2021 | $219.60 | $9.01 | 24.4 |
| 2020 | $236.34 | $10.29 | 23.0 |
| 2019 | $218.95 | $4.51 | 48.5 |
| 2018 | $165.71 | $8.09 | 20.5 |
| 2017 | $149.86 | $1.04 | 144.1 |
| 2016 | $73.67 | -$0.46 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $135.44B
- Enterprise value
- $135.63B
- PEG
- 2.34
- EV/revenue
- 10.5
Profitability and growth
- ROA
- 10.6%
- ROIC
- 23.1%
- Revenue growth (year over year)
- 11.8%
- Earnings growth (year over year)
- -39.0%
Financial health
- Total cash
- $6.3B
- Total debt
- $6.48B
- Current ratio
- 2.34
- Quick ratio
- 1.72
- Altman Z-Score
- 7.80
- Piotroski F-Score
- 4.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $595.36
- Median price target
- $609.50
- High price target
- $725.00
- Low price target
- $350.00
- Analysts with a price target
- 28
- Consensus
- Buy
- Forward EPS
- $19.92
- EPS estimate, current year
- $18.14
Shares and trading
- Beta
- 0.28
- Average volume
- 1.24M
- Shares outstanding
- 253.54M
- Float
- 252.77M
- Institutional ownership
- 98.1%
- Insider ownership
- 0.3%
- Short interest (% of float)
- 2.1%
- Short ratio (days)
- 3.55
